No Data
No Data
Despite Delivering Investors Losses of 17% Over the Past 1 Year, Shanghai Shenqi Pharmaceutical Investment Management (SHSE:600613) Has Been Growing Its Earnings
Wonder Pharmaceuticals: Semi-Annual Report 2024
Summary of the 2024 semi-annual report of Shanghai Magic Pharmaceutical Investment Management Co., Ltd.
shanghai shenqi pharmaceutical investment management (600613.SH) released its half-year performance with a net income of 37.837 million yuan, a year-on-year increase of 8.93%.
Shanghai Shenqi Pharmaceutical Investment Management (600613.SH) released its 2024 interim report, with a revenue of 1.11 billion yuan...
Shanghai Shenqi Pharmaceutical Investment Management (600613.SH): The net income for the first half of the year was approximately 37.84 million yuan, an increase of 8.93% compared to the same period last year.
Shanghai Shenqi Pharmaceutical Investment Management (600613.SH) announced that its revenue for the first half of 2024 was approximately 1.11 billion yuan, a decrease of 7.91% compared to the same period last year. The net income attributable to the shareholders of the listed company was approximately 37.84 million yuan, an increase of 8.93% compared to the same period last year. The basic earnings per share is 0.07 yuan.
Shanghai Shenqi Pharmaceutical Investment Management (600613.SH): Some formulated products contain ingredients of vitamins.
Shanghai Shenqi Pharmaceutical Investment Management (600613.SH) stated on the Investor Interactive Platform on August 14th that the company does not have vitamin raw material products. Some of the company's formulated products contain vitamin ingredients, and the main on-sale vitamin products include Ve Triple Oil Capsules and Compound Amino Acid (8) Vitamin (11) Capsules, among others. The company has noted the recent significant rise in vitamin raw material prices. The company will continue to strengthen market forecast analysis, monitor market trends, and effectively control costs by strategically purchasing bulk materials. Currently, the company's relevant raw material reserves are sufficient and will not affect market supply and normal operation of the company in the short term.
No Data
No Data